The FDA granted fast track status to givinostat for treating high-risk polycythemia vera, supporting its potential shown in ...

Valneva (VALN) stock is in focus as the U.S. recommends a pause in the company's chikungunya vaccine Ixchiq in adults 60+ ...

Thoughts of suicide was confirmed as a side effect of finasteride (Propecia, Proscar), the European Medicines Agency (EMA) ...

Italfarmaco S.p.A. announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ...

Treatment with givinostat has received fast track designation from the United States Food and Drug Administration for ...

Stealth BioTherapeutics Inc. (the "Company" or "Stealth"), a clinical-stage biotechnology company focused on the discovery, ...

The U.S. Food and Drug Administration (FDA) recently announced it plans to phase out animal testing in the development of monoclonal ...

Biotech Biohaven has signed a non-dilutive funding deal with Oberland Capital as it awaits an FDA ruling on its ...

The FDA extended aficamten's review by three months for REMS safety program finalization, causing Cytokinetics' stock to drop ...

The FDA has granted Fast Track designation to Italfarmaco S.p.A.’s givinostat for the treatment of patients with polycythemia vera (PV).

Donald Trump has promised to create a pro-AI environment, but even tech companies are frustrated by federal cuts that hamper regulatory processes. Paul Webster reports.